<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39386567</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2692-8205</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>25</Day></PubDate></JournalIssue><Title>bioRxiv : the preprint server for biology</Title><ISOAbbreviation>bioRxiv</ISOAbbreviation></Journal><ArticleTitle>Dynamics of Spike-Specific Neutralizing Antibodies Across Five-Year Emerging SARS-CoV-2 Variants of Concern Reveal Conserved Epitopes that Protect Against Severe COVID-19.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2024.09.22.614369</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2024.09.22.614369</ELocationID><Abstract><AbstractText>Since early 2020, several SARS-CoV-2 variants of concern (VOCs) continue to emerge, evading waning antibody mediated immunity produced by the current Spike-alone based COVID-19 vaccines. This caused a prolonged and persistent COVID-19 pandemic that is going to enter its fifth year. Thus, the need remains for innovative next generation vaccines that would incorporate protective Spike-derived B-cell epitopes that resist immune evasion. Towards that goal, in this study we (<i>i</i>) Screened the sequences of Spike among many VOCs and identified conserved and non-conserved linear B-cell epitopes; (<i>ii</i>) Compared titers and neutralization antibodies specific to these conserved and non-conserved B-cell epitopes from serum of symptomatic and asymptomatic COVID-19 patients that were exposed to multiple VOCs across the 5<sup>-</sup>year COVID-19 pandemic, and (<i>iii</i>) Compared protective efficacy of conserved versus non-conserved B-cell epitopes against the most pathogenic Delta variant in a "humanized" ACE-2/HLA transgenic mouse model. We found robust conserved B-cell epitope-specific antibody titers and neutralization in sera from asymptomatic COVID-19 patients. In contrast, sera from symptomatic patients contained weaker antibody responses specific to conserved B-cell epitopes. A multi-epitope COVID-19 vaccine that incorporated the conserved B-cell epitopes, but not the non-conserved B-cell epitopes, significantly protected the ACE2/HLA transgenic mice against infection and COVID-19 like symptoms caused by the Delta variant. These findings underscore the importance of conserved B-cell epitopes in generating robust protective immunity against severe COVID-19 symptoms caused by various VOCs, providing valuable insights for the development of broad-spectrum next generation Coronavirus vaccines capable of conferring cross-variant protective immunity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zayou</LastName><ForeName>Latifa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, CA 92697.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Cell Biology and Molecular Genetics, Faculty of Sciences, Ibn Zohr University, Agadir, Morocco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prakash</LastName><ForeName>Swayam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, CA 92697.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vahed</LastName><ForeName>Hawa</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Vaccines and Immunotherapies, TechImmune, LLC, University Lab Partners, Irvine, CA 92660; USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhanushkodi</LastName><ForeName>Nisha Rajeswari</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, CA 92697.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quadiri</LastName><ForeName>Afshana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, CA 92697.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belmouden</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Cell Biology and Molecular Genetics, Faculty of Sciences, Ibn Zohr University, Agadir, Morocco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemkhente</LastName><ForeName>Zohra</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Laboratory of Medical-Surgical, Biomedicine and infectiology Research, Faculty of Medicine and Pharmacy, Ibnou Zohr University, Agadir, Morocco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chentoufi</LastName><ForeName>Aziz</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, CA 92697.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gil</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Vaccines and Immunotherapies, TechImmune, LLC, University Lab Partners, Irvine, CA 92660; USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulmer</LastName><ForeName>Jeffrey B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Vaccines and Immunotherapies, TechImmune, LLC, University Lab Partners, Irvine, CA 92660; USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>BenMohamed</LastName><ForeName>Lbachir</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, CA 92697.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Biology and Biochemistry.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Immunology; the University of California Irvine, School of Medicine, Irvine, CA 92697.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Vaccines and Immunotherapies, TechImmune, LLC, University Lab Partners, Irvine, CA 92660; USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R41 AI138764</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI143348</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R43 AI174383</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI158060</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R43 AI124911</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI150091</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI143326</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI110902</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI147499</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>bioRxiv</MedlineTA><NlmUniqueID>101680187</NlmUniqueID><ISSNLinking>2692-8205</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Age</Keyword><Keyword MajorTopicYN="N">Antibodies</Keyword><Keyword MajorTopicYN="N">B cell epitopes</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Disease Severity</Keyword><Keyword MajorTopicYN="N">Gender</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>Conflict of interest: Studies of this report were supported by Public Health Service Research grants AI158060, AI150091, AI143348, AI147499, AI143326, AI138764, AI124911, and AI110902 from the National Institutes of Allergy and Infectious Diseases (NIAID) to LBM and by R43AI174383 to TechImmune, LLC. LBM has an equity interest in TechImmune, LLC., a company that may potentially benefit from the research results and serves on the company’s Scientific Advisory Board. LBM’s relationship with TechImmune, LLC., has been reviewed and approved by the University of California, Irvine in accordance with its conflict-of-interest policies.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>5</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39386567</ArticleId><ArticleId IdType="pmc">PMC11463540</ArticleId><ArticleId IdType="doi">10.1101/2024.09.22.614369</ArticleId><ArticleId IdType="pii">2024.09.22.614369</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prakash S, Srivastava R, Coulon PG, Dhanushkodi NR, Chentoufi AA, Tifrea DF, et al. Genome-Wide B Cell, CD4(+), and CD8(+) T Cell Epitopes That Are Highly Conserved between Human and Animal Coronaviruses, Identified from SARS-CoV-2 as Targets for Preemptive Pan-Coronavirus Vaccines. J Immunol. 2021;206(11):2566–82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8722450</ArticleId><ArticleId IdType="pubmed">33911008</ArticleId></ArticleIdList></Reference><Reference><Citation>Prakash S, Dhanushkodi NR, Zayou L, Ibraim IC, Quadiri A, Coulon PG, et al. Cross-Protection Induced by Highly Conserved Human B, CD4 (+,) and CD8 (+) T Cell Epitopes-Based Coronavirus Vaccine Against Severe Infection, Disease, and Death Caused by Multiple SARS-CoV-2 Variants of Concern. Frontiers In Immunololgy. 2024;29(12):45–56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10839970</ArticleId><ArticleId IdType="pubmed">38318166</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen SF, Ho YC. SARS-CoV-2: A Storm is Raging. J Clin Invest. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190904</ArticleId><ArticleId IdType="pubmed">32217834</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellocchi MC, Scutari R, Carioti L, Iannetta M, Marchegiani G, Piermatteo L, et al. Frequency of Atypical Mutations in the Spike Glycoprotein in SARS-CoV-2 Circulating from July 2020 to July 2022 in Central Italy: A Refined Analysis by Next Generation Sequencing. Viruses. 2023;15(8).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10458583</ArticleId><ArticleId IdType="pubmed">37632054</ArticleId></ArticleIdList></Reference><Reference><Citation>Desmecht S, Tashkeev A, El Moussaoui M, Marechal N, Peree H, Tokunaga Y, et al. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections. Front Immunol. 2022;13:863554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9195074</ArticleId><ArticleId IdType="pubmed">35711445</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma S, Vercruysse T, Sanchez-Felipe L, Kerstens W, Rasulova M, Bervoets L, et al. Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamsters. Nat Commun. 2022;13(1):6644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9636174</ArticleId><ArticleId IdType="pubmed">36333374</ArticleId></ArticleIdList></Reference><Reference><Citation>Washington NL, Gangavarapu K, Zeller M, Bolze A, Cirulli ET, Schiabor Barrett KM, et al. Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States. Cell. 2021;184(10):2587–94 e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8009040</ArticleId><ArticleId IdType="pubmed">33861950</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Iketani S, Zask A, Khanizeman N, Bednarova E, Forouhar F, et al. Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19. Nat Commun. 2022;13(1):1891.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8989888</ArticleId><ArticleId IdType="pubmed">35393402</ArticleId></ArticleIdList></Reference><Reference><Citation>Konings F, Perkins MD, Kuhn JH, Pallen MJ, Alm EJ, Archer BN, et al. SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for global discourse. Nat Microbiol. 2021;6(7):821–3.</Citation><ArticleIdList><ArticleId IdType="pubmed">34108654</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Thambiraja TS, Karuppanan K, Subramaniam G. Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein. J Med Virol. 2022;94(4):1641–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">34914115</ArticleId></ArticleIdList></Reference><Reference><Citation>Park T, Hwang H, Moon S, Kang SG, Song S, Kim YH, et al. Vaccines against SARS-CoV-2 variants and future pandemics. Expert Rev Vaccines. 2022;21(10):1363–76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9979704</ArticleId><ArticleId IdType="pubmed">35924678</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans JP, Liu SL. Challenges and Prospects in Developing Future SARS-CoV-2 Vaccines: Overcoming Original Antigenic Sin and Inducing Broadly Neutralizing Antibodies. J Immunol. 2023;211(10):1459–67.</Citation><ArticleIdList><ArticleId IdType="pubmed">37931210</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyke KE, Atmar RL, Islas CD, Posavad CM, Szydlo D, Paul Chourdhury R, et al. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. Cell Rep Med. 2022;3(7):100679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212999</ArticleId><ArticleId IdType="pubmed">35798000</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J, Zheng J, Zhang X, Tai W, Compas R, Deno J, et al. A T cell-based SARS-CoV-2 spike protein vaccine provides protection without antibodies. JCI Insight. 2024;9(5).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10972590</ArticleId><ArticleId IdType="pubmed">38456504</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz SA, Pohla H, Schendel DJ. A PCR-SSP method to specifically select HLA-A*0201 individuals for immunotherapeutic studies. Tissue antigens. 2000;55(6):532–47.</Citation><ArticleIdList><ArticleId IdType="pubmed">10902609</ArticleId></ArticleIdList></Reference><Reference><Citation>Olerup O, Zetterquist H. HLA-DRB1*01 subtyping by allele-specific PCR amplification: a sensitive, specific and rapid technique. Tissue antigens. 1991;37(5):197–204.</Citation><ArticleIdList><ArticleId IdType="pubmed">1685264</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchfink B, Reuter K, Drost HG. Sensitive protein alignments at tree-of-life scale using DIAMOND. Nat Methods. 2021;18(4):366–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8026399</ArticleId><ArticleId IdType="pubmed">33828273</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Jean S, Eltringham R, Madison J, Snyder P, Tu H, et al. Mutation-Specific SARS-CoV-2 PCR Screen: Rapid and Accurate Detection of Variants of Concern and the Identification of a Newly Emerging Variant with Spike L452R Mutation. J Clin Microbiol. 2021;59(8):e0092621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8288299</ArticleId><ArticleId IdType="pubmed">34011523</ArticleId></ArticleIdList></Reference><Reference><Citation>Duchene S, Featherstone L, Haritopoulou-Sinanidou M, Rambaut A, Lemey P, Baele G. Temporal signal and the phylodynamic threshold of SARS-CoV-2. Virus Evol. 2020;6(2):veaa061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454936</ArticleId><ArticleId IdType="pubmed">33235813</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin R. COVID-19 Vaccines vs Variants-Determining How Much Immunity Is Enough. JAMA. 2021;325(13):1241–3.</Citation><ArticleIdList><ArticleId IdType="pubmed">33729423</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271–80 e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Barton MI, MacGowan SA, Kutuzov MA, Dushek O, Barton GJ, van der Merwe PA. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics. Elife. 2021;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8480977</ArticleId><ArticleId IdType="pubmed">34435953</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Iketani S, Guo Y, Chan JF, Wang M, Liu L, et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2022;602(7898):676–81.</Citation><ArticleIdList><ArticleId IdType="pubmed">35016198</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang Q, et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature. 2020;584(7821):450–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">32698192</ArticleId></ArticleIdList></Reference><Reference><Citation>Carabelli AM, Peacock TP, Thorne LG, Harvey WT, Hughes J, Consortium C- GU, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 2023;21(3):162–77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9847462</ArticleId><ArticleId IdType="pubmed">36653446</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596(7871):276–80.</Citation><ArticleIdList><ArticleId IdType="pubmed">34237773</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen RE, Zhang X, Case JB, Winkler ES, Liu Y, VanBlargan LA, et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med. 2021;27(4):717–26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8058618</ArticleId><ArticleId IdType="pubmed">33664494</ArticleId></ArticleIdList></Reference><Reference><Citation>Cele S, Gazy I, Jackson L, Hwa SH, Tegally H, Lustig G, et al. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature. 2021;593(7857):142–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9867906</ArticleId><ArticleId IdType="pubmed">33780970</ArticleId></ArticleIdList></Reference><Reference><Citation>El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. The New England journal of medicine. 2021;385(19):1774–85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8482810</ArticleId><ArticleId IdType="pubmed">34551225</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. The New England journal of medicine. 2020;383(27):2603–15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Slaoui M, Hepburn M. Developing Safe and Effective Covid Vaccines - Operation Warp Speed’s Strategy and Approach. N Engl J Med. 2020;383(18):1701–3.</Citation><ArticleIdList><ArticleId IdType="pubmed">32846056</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao L, Hsiang TY, Dalmat RR, Ireton R, Morton JF, Stokes C, et al. Dynamics of SARS-CoV-2 VOC Neutralization and Novel mAb Reveal Protection against Omicron. Viruses. 2023;15(2).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9965505</ArticleId><ArticleId IdType="pubmed">36851745</ArticleId></ArticleIdList></Reference><Reference><Citation>Prakash S, Dhanushkodi NR, Zayou L, Ibraim IC, Quadiri A, Coulon PG, et al. Cross-protection induced by highly conserved human B, CD4(+), and CD8(+) T-cell epitopes-based vaccine against severe infection, disease, and death caused by multiple SARS-CoV-2 variants of concern. Front Immunol. 2024;15:1328905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10839970</ArticleId><ArticleId IdType="pubmed">38318166</ArticleId></ArticleIdList></Reference><Reference><Citation>Amanat F, Thapa M, Lei T, Ahmed SMS, Adelsberg DC, Carreño JM, et al. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. Cell. 2021;184(15):3936–48.e10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8185186</ArticleId><ArticleId IdType="pubmed">34192529</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitahara Y, Nakagama Y, Kaku N, Candray K, Michimuko Y, Tshibangu-Kabamba E, et al. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients. Microbiol Spectr. 2021;9(3):e0096521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8579840</ArticleId><ArticleId IdType="pubmed">34756082</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe. 2020;27(3):325–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7154514</ArticleId><ArticleId IdType="pubmed">32035028</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvatori G, Luberto L, Maffei M, Aurisicchio L, Roscilli G, Palombo F, Marra E. SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines. J Transl Med. 2020;18(1):222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7268185</ArticleId><ArticleId IdType="pubmed">32493510</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang JG, Su D, Song TZ, Zeng Y, Huang W, Wu J, et al. S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates. Nat Commun. 2021;12(1):1346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7921634</ArticleId><ArticleId IdType="pubmed">33649323</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelde A, Bilich T, Heitmann JS, Maringer Y, Salih HR, Roerden M, et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat Immunol. 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">32999467</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Xu Z, Lei Q, Lai DY, Hou H, Jiang HW, et al. Antibody landscape against SARS-CoV-2 reveals significant differences between non-structural/accessory and structural proteins. Cell Rep. 2021;36(2):109391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8233850</ArticleId><ArticleId IdType="pubmed">34242574</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi H, Liu B, Wang X, Zhang L. The humoral response and antibodies against SARS-CoV-2 infection. Nat Immunol. 2022;23(7):1008–20.</Citation><ArticleIdList><ArticleId IdType="pubmed">35761083</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>